CWBR [NASD]
CohBar, Inc.
Index- P/E- EPS (ttm)-0.21 Insider Own14.91% Shs Outstand86.73M Perf Week-7.84%
Market Cap16.97M Forward P/E- EPS next Y-0.21 Insider Trans0.00% Shs Float74.02M Perf Month-32.00%
Income-14.70M PEG- EPS next Q-0.03 Inst Own11.90% Short Float2.82% Perf Quarter-34.55%
Sales- P/S- EPS this Y30.30% Inst Trans-6.89% Short Ratio3.99 Perf Half Y-64.62%
Book/sh0.27 P/B0.65 EPS next Y-53.30% ROA-70.80% Target Price2.88 Perf Year-86.64%
Cash/sh0.25 P/C0.72 EPS next 5Y- ROE-78.80% 52W Range0.17 - 2.27 Perf YTD-49.59%
Dividend- P/FCF- EPS past 5Y-4.80% ROI- 52W High-92.23% Beta2.52
Dividend %- Quick Ratio19.50 Sales past 5Y- Gross Margin- 52W Low0.80% ATR0.02
Employees9 Current Ratio19.50 Sales Q/Q- Oper. Margin- RSI (14)31.28 Volatility12.04% 10.41%
OptionableNo Debt/Eq0.00 EPS Q/Q42.70% Profit Margin- Rel Volume0.80 Prev Close0.18
ShortableYes LT Debt/Eq0.00 EarningsMay 16 AMC Payout- Avg Volume523.16K Price0.18
Recom2.00 SMA20-16.28% SMA50-32.08% SMA200-68.86% Volume417,850 Change-2.00%
Mar-15-21Initiated Aegis Capital Buy $6
May-19-22 04:02PM  
May-16-22 04:01PM  
May-12-22 09:00AM  
May-02-22 09:00AM  
Mar-29-22 04:01PM  
Mar-15-22 09:00AM  
Jan-13-22 01:38PM  
Jan-03-22 09:00AM  
Dec-31-21 11:22AM  
Dec-17-21 09:00AM  
Nov-29-21 09:00AM  
Nov-19-21 09:47AM  
Nov-15-21 04:02PM  
Nov-03-21 08:33AM  
Nov-02-21 01:14AM  
Nov-01-21 09:00AM  
Oct-28-21 02:45PM  
08:45AM  
Oct-27-21 04:01PM  
Oct-13-21 09:00AM  
Sep-15-21 09:00AM  
Sep-08-21 09:00AM  
Sep-02-21 04:05PM  
Aug-20-21 09:46AM  
Aug-16-21 09:00AM  
Aug-12-21 12:50PM  
Aug-10-21 04:04PM  
04:02PM  
Aug-04-21 04:05PM  
Jul-14-21 09:00AM  
Jun-10-21 09:00AM  
May-17-21 04:02PM  
03:15PM  
May-03-21 09:00AM  
Apr-27-21 08:30AM  
Apr-22-21 09:56AM  
Apr-21-21 09:00AM  
Apr-14-21 09:00AM  
Mar-30-21 04:02PM  
02:45PM  
Mar-29-21 09:00AM  
Mar-16-21 04:05PM  
09:00AM  
Mar-12-21 09:00AM  
Mar-02-21 09:00AM  
Feb-25-21 09:00AM  
Feb-09-21 09:00AM  
Jan-20-21 09:00AM  
Jan-11-21 09:00AM  
Dec-09-20 09:00AM  
Nov-19-20 09:00AM  
Nov-16-20 04:01PM  
03:15PM  
Nov-09-20 03:30PM  
Nov-02-20 09:00AM  
07:35AM  
Oct-29-20 09:00AM  
Oct-27-20 09:00AM  
Oct-26-20 09:00AM  
Oct-15-20 04:05PM  
Oct-08-20 09:00AM  
Oct-05-20 09:00AM  
Sep-29-20 04:05PM  
Sep-10-20 04:05PM  
Sep-04-20 11:24AM  
Sep-03-20 08:45AM  
Aug-28-20 04:05PM  
Aug-26-20 08:30AM  
Aug-25-20 04:55PM  
Aug-24-20 09:00AM  
Aug-13-20 04:03PM  
Aug-05-20 09:00AM  
Jul-30-20 09:00AM  
Jul-07-20 09:00AM  
Jul-06-20 09:00AM  
Jun-30-20 09:00AM  
Jun-17-20 09:00AM  
Jun-02-20 09:00AM  
May-27-20 09:00AM  
May-14-20 04:02PM  
May-13-20 09:00AM  
May-05-20 09:00AM  
May-01-20 11:00AM  
Apr-30-20 09:00AM  
Apr-19-20 09:21AM  
Apr-14-20 08:30AM  
Mar-30-20 08:45AM  
Mar-12-20 04:02PM  
03:00PM  
08:30AM  
Mar-02-20 04:30PM  
Jan-28-20 09:00AM  
Jan-22-20 09:00AM  
Jan-08-20 09:00AM  
Dec-23-19 08:04PM  
Dec-16-19 09:00AM  
Nov-06-19 04:04PM  
Nov-05-19 09:00AM  
Oct-24-19 09:00AM  
Oct-23-19 08:45AM  
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Petkevich MishaDirectorOct 28Buy0.58167,00096,175407,609Nov 01 09:15 AM
Sarret Joseph J.Chief Executive OfficerAug 18Buy1.1220,00022,40020,000Aug 19 09:00 AM
Cundy Kenneth CChief Scientific OfficerAug 11Option Exercise0.7310,0007,30020,000Aug 13 04:02 PM
Cundy Kenneth CChief Scientific OfficerAug 11Sale2.0110,00020,10010,000Aug 13 04:02 PM